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ABSTRAK
Tujuan: mengetahui proporsi hiperurisemia pada pasien SKA serta kesintasan antara kelompok 
hiperurisemia dengan kelompok tidak hiperurisemia terhadap kejadian MACE pada pasien SKA selama 
perawatan di ICCU RS Cipto Mangunkusumo. Metode: penelitian dengan disain kohort retrospektif dengan 
analisis kesintasan, dilakukan terhadap 251 pasien SKA yang dirawat di ICCU RSUPNCM pada kurun waktu 
Januari 2009 – Desember 2011. Data klinis, laboratorium, elektrokardiografi, ekokardiografi, dan angiografi 
koroner dikumpulkan. Pasien diamati selama 7 hari perawatan di ICCU untuk melihat kejadian MACE dalam 
perawatan tersebut. MACE merupakan suatu kumpulan komplikasi yang meliputi syok kardiogenik, gagal 
jantung, stroke, infark berulang, sudden cardiac death, PCI ulang dalam perawatan, dan tindakan Coronary 
artery bypass graft (CABG). Perbedaan kesintasan kelompok pasien hiperurisemia dan tidak hiperurisemia 
ditampilkan dalam kurva Kaplan-Meier dan perbedaan kesintasan antara dua kelompok diuji dengan uji Log-
rank.Analisis multivariat dengan Cox proportional hazard regressiondilakukan untuk menghitung adjusted hazard 
ratio (dan interval kepercayaan 95%) antara pasien hiperurisemia dan tidak hiperurisemia untuk terjadinya 
MACE dengan memasukkan variabel-variabel perancu sebagai kovariat. Hasil: terdapat perbedaan kesintasan 
yang bermakna antara kelompok hiperurisemia dan tidak hiperurisemia pada uji Log-rank (p<0,001) dengan 
crude HR 2,7 (IK 95% 1,6–4) dan adjusted HR 2,67 (IK95% 1,6-4,3).Pada analisis kesintasan berdasarkan waktu 
terjadinya MACE, perbedaan kesintasan yang bermakna antara kelompok hiperurisemia (rerata kesintasan 6,05 
hari dengan SE 0,2 (IK 95% 5,6-6,4) dengan kelompok tanpa hiperurisemia (rerata kesintasan 7,33 hari dengan 
SE 0,1 (IK 95% 7,0-7,6). Kesimpulan: kesintasan pasien SKA dengan hiperurisemia lebih buruk dibandingkan 
tidak hiperurisemia selama perawatan ICCU.
Kata kunci: hiperurisemia, Sindrom Koroner Akut, Major Adverse Cardiac Event, kesintasan
ABSTRACT
Aim: to investigate the MACE-free survivals difference between hyperuricemic and normouricemic patients 
and to determine its role as risk factor for MACE occurrence in hospitalized acute coronary syndrome patients.
Methods: retrospective cohort study with survival analysis approach was conducted in 251 patients with acute 
coronary syndrome who were treated in ICCU Cipto Mangunkusumo Hospital during period from January 2009 
to December 2011. Clinical data, laboratory results, electrocardiography result, echocardiography result, and 
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coronary angiography were collected. Patients were observed and followed on major adverse cardiac event 
during 7 days of hospitalization in ICCU. Major adverse Cardiac Event is an event as a complication occur 
after acute coronary syndrome such as cardiogenic syock, acute heart failure, stoke, reinfarct during early 
ward treatment, sudden cardiac death, repeat PCI during ward ulang and perform coronary artery bypass graft 
(CABG) surgery. Difference in survival is shown in Kaplan-meier curve and difference in survival between groups 
were tested with Log-rank test, and multivariate analysis with Cox proportional hazard regression to calculate 
adjusted HR on major adverse cardiac event with confounding variables as covariates. Results: there was a 
significant difference in survival between hyperuricemia group and non-hyperuricemia group (Log-rank test 
(p<0.001)) with crude HR 2.7 (CI 95% 1.6–4) and adjusted HR 2.67 (CI 95% 1.6-4.3).There was significant 
difference in survival between hyperuricemia group (mean survival 6.05 days with SE 0.2 (CI 95% 5.6-6.4) 
and non-hyperuricemia group (mean survival 7.33 days with SE 0.1 (CI 95% 7.0-7.6). Conclusion: survival 
of patients suffering from ACS with hyperuricemia is worse compared to those without hyperuricemia during 
ICCU hospitalization.
Key words: hyperuricemia, acute coronary syndrome, major adverse cardiac event, survival.
INTRODUCTION
Coronary artery disease (CAD) is the leading 
cause of death in both western and developing 
countries such as Indonesia. Data from intensive 
cardiac care unit (ICCU) Cipto Mangunkusumo 
National General Hospital (RSUPNCM) in 2001-
2005 showed that the cases of acute coronary 
syndrome (ACS) increases from year to year.1 
In addition to the established risk factors of 
atherosclerosis, such as diabetes, hypertension, 
smoking and dyslipidemia, other factors such 
as hyperuricemia also have a significant role 
for the occurrence of CAD.2 Prevalence of 
hyperuricemia in the community is estimated 
between 2.3% to 17.6% with an average of 
5%. The mortality rate of patients with acute 
myocardial infarction with high uric acid levels 
increased by 3.7 times compared to patients with 
normal uric acid levels. Based on data from the 
First National Health and Nutrition Examination 
Study (NHANES), Freedman et al2 showed that 
increase of 1 mg/dl uric acid levels will follow 
by increasing risk of ischemic heart disease in 
women by 48%.2
Eventhough hyperuricemia has been shown to 
have roles in the formation of atherosclerosis and 
increasing incidence of coronary heart disease, 
its role in predicting prognosis in acute coronary 
syndrome (ACS) patients has not been widely 
studied. Hyperuricemia can lead to increase risk 
of major adverse cardiac events (MACE) in ACS 
patients due to free radical formation, platelet 
adhesiveness, and cardiomyocyte dysfunction 
and hyperptrophy.3,4 Thus, the information 
regarding uric acid levels potentially important 
to predict the clinical course of ACS patients and 
would help clinicians to stratify patients into their 
risk of worse outcomes.
The aims of this study are to investigate 
the MACE-free survivals difference between 
hyperuricemic and normouricemic patients and 
to determine its role as risk factor for MACE 
occurrence in hospitalized acute coronary 
syndrome patients. The results of this study are 
expected to enhance our knowledge regarding 
the role of uric acid level on outcomes of 
patients with acute coronary syndrome and thus 
can be use by clinician in determining patient’s 
prognosis.
METHODS
A retrospective cohort study was conducted 
among acute coronary syndrome (ACS) patients 
admitted to intensive cardiac care unit (ICCU) 
Cipto Mangunkusumo Hospital, Jakarta, 
between 2007 to 2010 period. Patients were 
excluded if they have diagnosis of heart failure, 
acute cerebrovascular accident (CVA) or stroke, 
cardiogenic shock, as well as died in the first day 
of admission based on medical record data.
This study was conducted according to 
Declaration of Helsinki and was obtained 
ethical clearance from Health Research Ethics 
Committee, Faculty of Medicine Universitas 
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Indonesia/Cipto Mangunkusumo Hospital, 
Jakarta.
Clinical and Uric Acid Data Collection
Data obtained from the medical records 
including history taking associated with 
ischemia symptoms, head to toe physical 
examination, and laboratory examination. The 
laboratory examinations include peripheral 
blood examination, uric acid, blood urea nitrogen 
(BUN), creatinine, ALT, AST, random blood 
glucose, electrolyte, lipid profile, cardiac enzyme 
includes CK-CKMB and troponin T. Other 
examinations assessed are electrocardiography, 
chest x-ray, echocardiography, and coronary 
angiography.
Outcome Measure
Primary outcome of this study was major 
adverse cardiac events (MACE), defined as 
as a complication which occurs after acute 
coronary syndrome such as cardiogenic syock, 
acute heart failure, stroke, reinfarct during early 
hospitalization, sudden cardiac death, repeat 
PCI during hospitalization, and coronary artery 
bypass graft (CABG) surgery. Occurrence and 
timing of these events were collected from 
medical records.
Statistical Analysis
Based on an assumption 10% MACE will be 
occurred in normourisemic group, with type 1 
error of 5% and power of 20%, this study needs at 
least 250 subjects to significantly detect hazards 
difference of 7% between normourisemic and 
hyperurisemic groups.
The  surv iva ls  d i ffe rence  be tween 
hyperuricemic and normouricemic groups was 
presented by Kaplan-Meier Curve and analyzed 
using log-rank test. The association between ucic 
acid levels and MACE occurrence was analyzed 
using multivariate Cox’s regression model to 
obtained its hazard ratios (HR), before and after 
adjusted for several confounders, i.e. decrease of 
renal function, dyslipidemia, diabetes mellitus, 
and hypertension.
All analysis performed using satatistical 
package for social solution (SPSS) software 
version 17.
RESULTS
Recruitment of Subjects and Baseline 
Characteristics
During Januari 2009 to December 2011 
period, there were 360 patients admitted to 
ICCU ward Cipto Mangunkusumo Hospital 
with identified medical record and among these 
109 patients were excluded due to MACE 
occurrence before the observation period. Of 
251 subjects included in this study, the mean 
age was 56,24 (standard deviation 11.18) years 
old and 87 (67.3%) of subjects were male. 
Demographic, clinical, and cardiovascular-
related characteristics according to uric acid 
levels were shown in Table 1.
Tabel 1. Demographic, clinical, and cardiovascular-related 
characteristic
Characteristics Hyperuricemia (n=125)
non-
hyperuricemia 
(n=126)
Sex (male), n (%) 87 (69,6) 82 (65,1)
Age (year),  
mean (SD)
58 (9,90) 56.2 (11.18)
Age category, n (%)
 - <45 years old 10 (8) 16 (12.7)
 - 45-60 years old 71 (56.8) 67 (53.2)
 - > 60 years old 44 (35.2) 43 (34.1)
Occupation, n (%)
 - Civil servant 39 (31.2) 38 (30.2)
 - Retired 27 (21.6) 26 (20.6)
 - Private employee 22 (17.6) 30 (23.8)
 - Housewife 17 (13.6) 24 (19.0)
 - Unemployed 19 (15.2) 8 (6.3)
 - Others 1 (0.8) 0 (0.0)
Risk factors, n (%)
 - Hypertension 85 (68.0) 78 (61.9)
 - Smoking 71 (56.8) 71 (56.3)
 - DM 45 (36.0) 42 (33.3)
 - Dyslipidemia 45 (36.0) 44 (34.9)
 - History of CV 
disease
33 (14.4) 15 (11.9)
ACS category, n (%)
 - STEMI 42 (33.6) 58 (46.0)
 - NSTEMI 41 (32.8) 19 (15.1)
 - UAP 42 (33.6) 49 (38.4)
Infarct size, n (%)
 - Extensive 79 (63.2) 83 (65.9)
 - Non-extensive 46 (36.8) 43 (34.1)
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According to Table 1, there were no 
differences regarding demographic and 
clinical characteristics between hyperuricemic 
and normouricemic patients, as well as on 
cardiovascular risk factors. Some differences 
were found on types of ACS (more ST-elevation 
myocard infarction in normouricemic patients) 
and more revascularitation done in normouremic 
patients.
MACE-free Survival and Association between 
Uric Acid and MACE Occurrence
Kaplan-Meier survival curve (Figure 1) 
showed there was significant difference of 7-days 
MACE-free survival between hyperuricemic 
and normouricemic groups; 60% vs. 82%, 
respectively (p log-rank <0.001). There was also 
mean MACE-free survival difference between 
groups; 6.05 (SE 0.2) days in hyperuricemic 
group vs. 7.33 (SE 0.1) days in normouremic 
group.
Hiperuricemia increase the hazard for 
MACE occurrence both in bivariate analysis 
Normal
Increase
Figure 1. Kaplan-Meier survival analysis in MACE incidence 
on hyperuricemia group and non-hyperuricemia group
Tabel 1. Demographic, clinical, and cardiovascular-related 
characteristic
Characteristics Hyperuricemia (n=125)
non-
hyperuricemia 
(n=126)
Infarct location, n (%)
 - Ext. anterior 56 (44.8) 50 (39.7)
 - Inferior 26 (20.8) 34 (27.0)
 - Anterioseptal 18 (14.4) 26 (20.6)
 - Lateral 15 (12.0) 3 (2.4)
 - Anterior 5 (4.0) 7 (5.6)
 - Others 5 (4.0) 6 (4.8)
Revascularization, 
n (%)
28 (22.4) 44 (34.9)
LVEF, mean (SD) 45.8 (13.62) 48.9 (11.43)
LVEF, n (%)
 - >40 75 (60.0) 97 (77.0)
 - ≤40 50 (40.0) 29 (23.0)
Kidney function 
(eGFR), mean (SD)
66.3 (30.66) 72.1 (36.97)
Kidney function (eGFR), n (%)
 - <60 54 (43.2) 46 (36.5)
 - ≥60 71 (56.8) 80 (63.5)
Diuretic consumption, 
n (%) 9 (7.2) 3 (2.4)
MACE, n (%) 52 (41.6) 23 (18.3)
Normal
Increase
Figure 2. Hazard function reflecting the Hazard ratio of both 
group after adjustment of confounding variable
(crude hazard ratio [HR] 2.67 (95% confidence 
interval 1.6 to 5.4) and multivariate analysis 
after adjusted for renal function, dyslipidemia, 
hypertension, and diabetes mellitus (adjusted HR 
2.70 (95% CI 1.60 to 4.50).
DISCUSSION
To our knowledge, this is the first study 
in a cohort acute coronary syndrome patients 
admitted to ICCU to assess whether high uric 
acid levels at admission might increase risk for 
major adverse cardiac events (MACE) during 
hospitalization, using survival approach to 
describe and analyze the MACE-free survivals 
between hyperurisemic and normouricemic 
groups.
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Despite of similar baseline characteristics 
between hyperurisemic and normourisemic 
groups, there was different MACE-free survival 
rates among these groups even after adjustment for 
several confounders. Patients with hyperuricemia 
having more than 20% lower of MACE-free 
survival compared to normouremic patients, and 
in average the MACE were occurred 1.25 days 
earlier during hospitalization in hyperurisemic 
patients. Using Cox’s proportional hazard 
regression analysis, we showed that the hazard 
for MACE occurrence was almost 3 times higher 
in hyperurisemic compared to normourisemic 
patients. The results were inline with other 
similar studies from Dunkelgrun et al.4 and 
Bickel et al.5 who also showed that MACE were 
more common and more rapidly occurred in 
patients with hyperuricemia.
There are several explanations regarding 
the findings of this study. First, hyperurisemia 
can causes free radical formation and fat 
peroxidation, thus enhanced the endothelial 
dyfunction.4 Second, study by Kaya et al.6 has 
showed that there is an association between 
hyperurisemia with poor coronary collateral 
vascularization, due to inflammation process.
Using cohort design, we could ensure that the 
exposure (high uric acid level on admission) was 
preceed the outcome (MACE after 24 hours since 
admission) which is fulfill first Hill’s criteria for 
causation in epidemiologic study. Another Hill’s 
criteria which also met by this study are strong 
relationship represent by adjusted HR of 2.7 with 
quite narrow confidence interval and the results 
are consistent with other studies.7-10 Biological 
plausibilities were also can be expected trough 
the effect of hyperuricemia on oxidative stress 
and endothelial dysfunction.11 Unfortunately, 
we cannot prove dose-response relationship 
and challenge-dechallenge effect which are also 
important criteria for causation.
As a retrospective cohort study, we cannot 
obtain all important information data regarding 
risk factors, confounding factors, and laboratory 
tests; thus the analysis was only performed on 
available data and residual confounding could 
be expected. Despite this limitation, as the 
medical record system of ICCU patient’s in our 
hospital is valid as proved in previous studies,7 
the results of this study could be expected valid 
as well. Furthermore, Cox’s regression as basis 
of multivariate analysis used in this study was 
able to explore the risks for MACE occurrence in 
a more representative way compared to logistic 
regression analysis.
CONCLUSION
There was MACE-free survival difference 
between hyperuricamic and normouricemic 
patients and hyperuricemia is a risk factor 
for major adverse cardiac events (MACE) in 
hospitalized acute coronary syndrome patients.
Doctor should consider the uric acid result 
data in managing ACS patients to stratify the risk 
of MACE. The uric acid examination should be 
taken when patients admitted in the hospital in 
order to optimal management of ACS patients 
in reducing morbidity and mortality rate. It is 
necessary to have research on the relations of 
hyperuricemia to the MACE event with longer 
time of investigations in ACS patient after patient 
discharge from the hospital. It is necessary to 
have continuing research on prognostic factors 
MACE events to reduce mortality rate, morbidity 
rate, and cost. It is necessary to have clinical trial 
research on the importance of prescribing uric 
acid lowering drugs to the MACE events in ACS 
patients during inpatient or outpatient setting.
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